碳离子放疗治疗直肠癌术后盆腔复发的前瞻性临床试验五年结局(GUNMA 0801)
该前瞻性临床试验纳入28例直肠癌术后盆腔复发无远处转移患者,行碳离子放疗总剂量73.6 Gy(相对生物效应)分16次。中位随访51.2个月,5年总生存率和局部控制率分别为50%和83%,4例局部复发,17例死于直肠癌;晚期毒性包括2例3级盆腔感染和9例2级周围神经病变。作者认为碳离子放疗可能是安全有效的治疗选择。
要点
- 碳离子放疗总剂量73.6 Gy(相对生物效应)分16次,用于直肠癌术后盆腔复发。
- 5年总生存率50%,5年局部控制率83%。
- 晚期毒性:2例3级盆腔感染,9例2级周围神经病变。
核心结论
- 对碳离子放疗治疗直肠癌术后盆腔复发的前瞻性临床试验更新分析证实了其长期疗效和安全性。
- 作者认为碳离子放疗可能是直肠癌术后盆腔复发的安全有效的治疗选择。
研究设计与样本
- 前瞻性临床试验(GUNMA 0801),纳入28例患者。
- 纳入标准为确诊直肠癌盆腔复发无远处转移、原发灶及区域淋巴结根治性切除无大体或镜下残留、影像学可测量肿瘤。
- 所有患者碳离子放疗总剂量73.6 Gy(相对生物效应)分16次。
主要发现
- 全部患者中位随访51.2个月,生存患者中位随访69.2个月。
- 分析时随访率96.4%。
- 5年总生存率50%,5年局部控制率83%。
- 4例局部复发,17例死于直肠癌。
- 晚期毒性:2例发生3级盆腔感染,9例发生2级周围神经病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Carbon-ion radiotherapy (C-ion RT) is associated with favorable clinical outcomes for the pelvic recurrence of rectal cancer. However, few long-term follow-up studies after C-ion RT have been conducted. Hence, we performed an updated analysis of a prospective clinical trial of C-ion RT for the postoperative pelvic recurrence of rectal cancer. MATERIALS AND METHODS: The study included 28 patients. Inclusion criteria were patients with confirmed pelvic recurrence of rectal cancer without distant metastasis; those who underwent curative resection of their primary disease and regional lymph nodes without gross or microscopic residual disease; and those who had radiographically measurable tumors. The total dose of C-ion RT for all the patients was 73.6 Gy (relative biological effectiveness) administered in 16 fractions. RESULTS: The median follow-up duration in all patients and those who survived were 51.2 and 69.2 months, respectively. The follow-up rate at the time of analysis was 96.4%. The 5-year overall survival and local control rates were 50% and 83%, respectively. Four patients had local recurrence, and 17 died of rectal cancer. Regarding late toxicities, two patients developed grade 3 pelvic infection, and nine developed grade 2 peripheral neuropathy. CONCLUSION: Our updated analysis of a prospective clinical trial of C-ion RT for postoperative pelvic recurrence of rectal cancer confirmed its long-term efficacy and safety. These results suggest that C-ion RT may be a safe and effective treatment option for the postoperative pelvic recurrence of rectal cancer.
引用
- Shiba S, Okamoto M, Shibuya K, et al. Five-year outcomes in carbon-ion radiotherapy for postoperative pelvic recurrence of rectal cancer: A prospective clinical trial (GUNMA 0801). Clin Transl Radiat Oncol. 2023. PMID: 38033760. doi:10.1016/j.ctro.2023.100701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。